Evidence map›Paper›PMID 32368114›Full record

ArticleDiabetes, metabolic syndrome and obesity : targets and therapy2020

Nomogram for the Risk of Diabetic Nephropathy or Diabetic Retinopathy Among Patients with Type 2 Diabetes Mellitus Based on Questionnaire and Biochemical Indicators: A Cross-Sectional Study.

Rong Shi, Zheyun Niu, Birong Wu, Taotao Zhang, Dujie Cai, Hui Sun, Yuhong Hu, Ruohui Mo, Fan Hu

Abstract read
In one paragraph

Article in Diabetes, metabolic syndrome and obesity : targets and therapy, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
20citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

20 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Association Between Serum Albumin Level and Microvascular Complications of Type 2 Diabetes Mellitus.Diabetes, metabolic syndrome and obesity : targets and therapy · 2022
    Article
  17. Construction of Predictive Model for Type 2 Diabetic Retinopathy Based on Extreme Learning Machine.Diabetes, metabolic syndrome and obesity : targets and therapy · 2022
    Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Rong ShiSchool of Public Health, Shanghai University of Traditional Chinese Medicine, Shanghai, People's Republic of China.
Zheyun NiuSchool of Public Health, Shanghai University of Traditional Chinese Medicine, Shanghai, People's Republic of China.
Birong WuSchool of Public Health, Shanghai University of Traditional Chinese Medicine, Shanghai, People's Republic of China.
Taotao ZhangSchool of Public Health, Shanghai University of Traditional Chinese Medicine, Shanghai, People's Republic of China.
Dujie CaiSchool of Public Health, Shanghai University of Traditional Chinese Medicine, Shanghai, People's Republic of China.
Hui SunSchool of Public Health, Shanghai University of Traditional Chinese Medicine, Shanghai, People's Republic of China.
Yuhong HuSchool of Public Health, Shanghai University of Traditional Chinese Medicine, Shanghai, People's Republic of China.
Ruohui MoSchool of Public Health, Shanghai University of Traditional Chinese Medicine, Shanghai, People's Republic of China.
Fan HuSchool of Public Health, Shanghai University of Traditional Chinese Medicine, Shanghai, People's Republic of China.ORCID 0000-0002-7929-6953

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeThis study aimed to develop a diabetic nephropathy (DN) or diabetic retinopathy (DR) incidence risk nomogram in China's population with type 2 diabetes mellitus (T2DM) based on a community-based sample.

methodsWe carried out questionnaire evaluations, physical examinations and biochemical tests among 4219 T2DM patients in Shanghai. According to the incidence of DN and DR, 4219 patients in our study were divided into groups of T2DM patients with DN or DR, patients with both, and patients without any complications. We successively used least absolute shrinkage and selection operator regression analysis and logistic regression analysis to optimize the feature selection for DN and DR. To ensure the accuracy of the results, we carried out multivariable logistic regression analysis of the above significant risk factors on the sample data for both DN and DR. The selected features were included to establish a prediction model. The C-index, calibration plot, curve analysis and internal validation were used to validate the distinction, calibration, and clinical practicality of the model.

resultsThe predictors in the prediction model included disease course, body mass index (BMI), total triglycerides (TGs), systolic blood pressure (SBP), postprandial blood glucose (PBG), haemoglobin A1C (HbA1c) and blood urea nitrogen (BUN). The model displayed moderate predictive power with a C-index of 0.807 and an area under the receiver operating characteristic curve of 0.807. In internal verification, the C-index reached 0.804. The risk threshold was 16-75% according to the analysis of the decision curve, and the nomogram could be applied in clinical practice.

conclusionThis DN or DR incidence risk nomogram incorporating disease course, BMI, TGs, SBP, PBG, HbA1c and BUN can be used to predict DN or DR incidence risk in T2DM patients. The research team has developed an online app based on a clinical prediction model incorporating risk factors for rapid and simple prediction.

Indexed as

diabetic nephropathydiabetic retinopathynomogrampredictorstype 2 diabetes mellitus

Identifiers

PMID32368114
PMCPMC7182465

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.